Durvalumab Mixture Improves Outcomes in Sufferers With ES-SCLC
[ad_1] Luis Paz-Ares, MD, PhD At the 2019 ESMO Congress, updated information from the phase III CASPIAN trial demonstrated delays in the improvement of new lesions and improvements in patient-reported […]